SOPHiA GENETICS (NASDAQ:SOPH) Releases Quarterly Earnings Results, Hits Estimates

SOPHiA GENETICS (NASDAQ:SOPH) posted its quarterly earnings data on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.23), Zacks reports. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. SOPHiA GENETICS updated its FY 2025 guidance to EPS.

SOPHiA GENETICS Trading Down 2.7 %

SOPH opened at $3.57 on Tuesday. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. SOPHiA GENETICS has a 52 week low of $2.70 and a 52 week high of $7.37. The business’s 50 day moving average is $3.58 and its two-hundred day moving average is $3.56. The firm has a market cap of $233.39 million, a price-to-earnings ratio of -3.28 and a beta of 1.03.

Wall Street Analyst Weigh In

Separately, Craig Hallum assumed coverage on shares of SOPHiA GENETICS in a research note on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price target for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $7.40.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.